Prostaxen 60 mg Tablet (Apalutamide): Clinical Data, Safety Protocols, & Global Price

Prostaxen 60 mg is a potent, next-generation non-steroidal androgen receptor (AR) inhibitor. It is specifically indicated for the treatment of adult men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) and Metastatic Castration-Sensitive Prostate Cancer (mCSPC). By selectively binding to the ligand-binding domain of the androgen receptor, Prostaxen inhibits AR nuclear translocation and DNA binding, effectively halting the cellular proliferation signaled by androgens. This targeted mechanism significantly delays the progression to metastatic disease and improves overall survival in advanced prostate cancer populations.

Commentary by Dr. Salma Elreedy, Board-Certified Oncologist

“In the traditional management of prostate cancer, we often faced a ‘therapeutic ceiling’ once a patient developed resistance to primary androgen deprivation therapy (ADT). The transition from nmCRPC to metastatic disease was a period of high anxiety for both clinicians and patients. The advent of second-generation AR inhibitors like Apalutamide represents a paradigm shift. We are no longer just lowering testosterone; we are fundamentally blocking the receptor’s ability to drive malignancy.

In my practice, the clinical utility of Apalutamide lies in its ability to extend Metastasis-Free Survival (MFS) while maintaining a high quality of life. However, managing the unique side-effect profile—specifically the risk of falls and skin rash—requires proactive patient education. The introduction of high-quality generic equivalents like Prostaxen from Everest Pharmaceutical is a vital development. It ensures that this high-efficacy targeted therapy remains accessible to a global patient base, removing the financial toxicity that often accompanies long-term oncological care.“

FDA Approved Indications, Dosage & Adverse Event Management, Clinical Efficacy, and Safety Protocols

Precise Indications & Biomarker Requirements

Treatment with Prostaxen requires a confirmed diagnosis of prostate cancer in specific clinical states:

• nmCRPC: Patients must have non-metastatic disease as confirmed by conventional imaging (CT/MRI/Bone Scan) and a rising Prostate-Specific Antigen (PSA) despite castrate levels of testosterone (< 50 ng/dL).
• mCSPC: Patients with metastatic disease who still respond to testosterone suppression.
• Companion Diagnostic: No specific genetic biomarker (like BRCA) is required, but a documented castrate-resistant status or metastatic sensitivity is mandatory.

Mechanism of Action & Pharmacokinetics (ADME)

Apalutamide works via triple-action AR inhibition: blocking androgen binding, preventing AR nuclear translocation, and inhibiting AR-mediated DNA transcription.

• Absorption: Median T_max is 2 hours. It can be taken with or without food.
• Distribution: 96% protein bound, primarily to albumin.
• Metabolism: Metabolized primarily by CYP3A4 and CYP2C8 to form N-desmethyl apalutamide (an active metabolite).
• Excretion: 65% eliminated in urine; 24% in feces.
• Half-life: Approximately 3 days at steady state.

Dosage & Adverse Event (AE) Management

The standard dose of Prostaxen is 240 mg (four 60 mg tablets) administered orally once daily. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or have had a bilateral orchiectomy. Prostaxen 60 mg tablets should be swallowed whole. Do not crush, chew, or split the tablets.

Clinical Efficacy & Real-World Data

The clinical profile of Apalutamide was solidified in two landmark Phase 3 trials:

• SPARTAN (nmCRPC): Demonstrated a median Metastasis-Free Survival (MFS) of 40.5 months vs. 16.2 months in the placebo group (Hazard Ratio: 0.28).
• TITAN (mCSPC): Showed a 33% reduction in the risk of death (Hazard Ratio: 0.67) and significantly improved Radiographic Progression-Free Survival (rPFS).

Real-World Evidence (RWE): Post-marketing observations confirm that Apalutamide maintains its efficacy in “real-world” elderly populations, though there is a slightly higher incidence of fatigue and falls compared to clinical trial cohorts, emphasizing the need for geriatric assessment during treatment.

Drug-Drug Interaction (DDI) Matrix

Apalutamide is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9.

Precautions & Special Populations

• Embryo-Fetal Toxicity: Prostaxen is not indicated for use in females. It can cause fetal harm. Males with female partners of reproductive potential must use effective contraception during treatment and for 3 months after the last dose.
• Ischemic Heart Disease: Increased risk observed in trials. Monitor for signs of cardiac ischemia and optimize management of cardiovascular risk factors (BP, lipids).
• Renal/Hepatic Impairment: No dose adjustment is needed for mild-to-moderate impairment. Use with caution in severe renal impairment or severe hepatic impairment (Child-Pugh C).
• Storage: Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture by keeping tablets in the original bottle.

Manufacturing Quality Assurance, Named Patient Global Access, & Brand Comparison

Everest Pharmaceuticals Manufacturing Insights

Everest Pharmaceutical utilizes advanced synthesis and tableting technologies to produce Prostaxen. The facility is WHO-GMP and ISO 9001:2015 certified, ensuring that every batch undergoes rigorous dissolution testing and bioequivalence studies to match the kinetic profile of the innovator brand. High-Performance Liquid Chromatography (HPLC) is standard for all API verification processes.

Global Access via Named Patient Program (NPP)

Patients can access Prostaxen through the Named Patient Program (NPP), which facilitates the legal importation of medications for personal use:

• Oncology Consultation: Obtain a valid prescription from a registered oncologist.
• Letter of Medical Necessity (LMN): Documentation outlining the clinical need for Apalutamide.
• Permit Acquisition: Apply for a personal import license from the local Drug Regulatory Authority (e.g., DGDA in Bangladesh).
• Logistics: Importation via certified pharmaceutical exporters using temperature-controlled shipping.

Everest (Prostaxen) vs Innovator (Erleada)

People Also Want to Know